- Home
- RYTM
as 05-17-2024 4:00pm EST
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 2.3B | IPO Year: | 2017 |
| Target Price: | $54.33 | AVG Volume (30 days): | 566.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.50 - $52.57 | Next Earning Date: | 05-07-2024 |
| Revenue: | $91,926,000 | Revenue Growth: | 173.52% |
| Revenue Growth (this year): | 77.78% | Revenue Growth (next year): | 54.57% |
Share on Social Networks:
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shulman Joseph | RYTM | Chief Technical Officer | Mar 21 '24 | Sell | $40.34 | 18,235 | $735,599.90 | 30 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Mar 20 '24 | Sell | $39.33 | 9,066 | $356,565.78 | 6,852 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Mar 20 '24 | Sell | $38.22 | 9,169 | $350,439.18 | 15,918 | SEC Form 4 |
| German Christopher Paul | RYTM | Corporate Controller & CAO | Mar 20 '24 | Sell | $41.76 | 368 | $15,367.68 | 795 | SEC Form 4 |
| Mazabraud Yann | RYTM | EVP, Head of International | Mar 19 '24 | Sell | $39.22 | 16,000 | $627,520.00 | 24,495 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 18,265 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 25,087 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Mar 19 '24 | Sell | $39.22 | 15,515 | $608,498.30 | 97,939 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $49.84 | 473 | $23,574.32 | 2,984 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $51.38 | 791 | $40,641.58 | 3,457 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $51.52 | 100 | $5,152.00 | 2,686 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $50.88 | 23,397 | $1,190,502.53 | 2,786 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $50.14 | 48,177 | $2,415,503.24 | 26,183 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '24 | Sell | $48.24 | 100 | $4,824.00 | 74,360 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 9 '24 | Sell | $51.38 | 1,209 | $62,118.42 | 80,413 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 9 '24 | Sell | $49.82 | 709 | $35,322.38 | 79,704 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 1 '24 | Sell | $45.06 | 1,324 | $59,659.44 | 2,614 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 1 '24 | Sell | $45.06 | 1,616 | $72,816.96 | 75,215 | SEC Form 4 |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Feb 1 '24 | Sell | $45.06 | 1,492 | $67,229.52 | 3,021 | SEC Form 4 |
| Meeker David P | RYTM | President and CEO | Feb 1 '24 | Sell | $45.06 | 4,361 | $196,506.66 | 121,099 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Dec 27 '23 | Sell | $50.00 | 7,926 | $396,318.23 | 0 | SEC Form 4 |
| Shulman Joseph | RYTM | Chief Technical Officer | Dec 27 '23 | Sell | $50.01 | 5,015 | $250,796.14 | 1,126 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Dec 5 '23 | Sell | $40.00 | 20,000 | $800,000.00 | 61,406 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Dec 5 '23 | Sell | $35.06 | 7,026 | $246,359.66 | 61,406 | SEC Form 4 |
| Smith Hunter C | RYTM | Chief Financial Officer | Nov 14 '23 | Sell | $30.38 | 12,000 | $364,573.20 | 61,406 | SEC Form 4 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Insider Monkey
12 days ago
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
GuruFocus.com
12 days ago
Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
Thomson Reuters StreetEvents
12 days ago
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call
MT Newswires
13 days ago
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell
GuruFocus.com
13 days ago
Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges
Zacks
13 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
13 days ago